UK markets close in 3 hours 12 minutes
  • FTSE 100

    7,023.93
    +6.46 (+0.09%)
     
  • FTSE 250

    22,249.54
    -74.65 (-0.33%)
     
  • AIM

    1,220.38
    -9.42 (-0.77%)
     
  • GBP/EUR

    1.1669
    +0.0033 (+0.28%)
     
  • GBP/USD

    1.3876
    +0.0067 (+0.48%)
     
  • BTC-GBP

    23,344.57
    -1,066.28 (-4.37%)
     
  • CMC Crypto 200

    791.78
    -148.16 (-15.76%)
     
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • DOW

    33,290.08
    -533.32 (-1.58%)
     
  • CRUDE OIL

    71.72
    +0.08 (+0.11%)
     
  • GOLD FUTURES

    1,780.90
    +11.90 (+0.67%)
     
  • NIKKEI 225

    28,010.93
    -953.15 (-3.29%)
     
  • HANG SENG

    28,489.00
    -312.27 (-1.08%)
     
  • DAX

    15,541.97
    +93.93 (+0.61%)
     
  • CAC 40

    6,583.06
    +13.90 (+0.21%)
     

Global $125+ Billion Oncology Diagnostics Markets to 2025 with Abbott, Agilent, bioMerieux, General Electric, Roche, Siemens and Thermo Fisher Scientific Dominating

·5-min read

Dublin, June 04, 2021 (GLOBE NEWSWIRE) -- The "Global Oncology Diagnostics Market 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global oncology diagnostics market should reach $128.3 billion by 2025 from $86.7 billion in 2020 at a compound annual growth rate (CAGR) of 8.1% for the forecast period of 2020 to 2025.

This report examines the current and forecasted market potential for oncology diagnostics. It offers a detailed analysis of the market background, competitive environment, technological advancement, drivers and restraints and market growth trends. This report includes market projections through 2025, detailing the market share for oncology diagnostics based on the product, application and end user.

The global market is growing due to the increasing prevalence of cancer, a rise in the world's elder population, rising awareness and growing technological advancements in various fields: biomarkers, imaging, biopsy and endoscopy. Advances in science and technology platforms are expected to progress faster in oncology than in other disease areas, due to terminal disease prevalence and the corresponding rise in patient risk tolerance.

According to the WHO, cancer is the second leading cause of death, globally, accounting for around one in six deaths in 2018. Prostate, colorectal, stomach, lung and liver cancer are the most common types of cancer in men, while colorectal, breast, lung, cervical and thyroid cancer are the most common among women.

The cancer burden continues to rise, globally, exerting tremendous emotional, physical and financial strain on families, individuals, communities and health systems. Many health systems in low and middle-income countries are not prepared to manage this burden. Large numbers of cancer patients, worldwide, do not have access to timely quality treatment and diagnosis. In countries where health systems are robust, survival rates of many types of cancers are improving due to accessible early detection, quality treatment and survivorship care.

Delayed cancer treatment can result in a considerable decrease in survival. The oncology diagnostics market is booming and very competitive, with many big and small players operating in different market segments. A strong need for new diagnostic tools exists to allow earlier detection with higher specificity and higher sensitivity. New startups are founded every year with the aim of developing the next big diagnostic technology.

Healthcare facilities have adopted stricter safety practices to reduce the risk of exposing people to COVID-19. At the start of the coronavirus pandemic, elective medical procedures, including cancer diagnosis, were primarily put on hold to prioritize urgent needs and reduce the risk of the virus spread in healthcare settings. One result of this has been a substantial decline in cancer diagnosis and screening.

Many cancer diagnoses and treatment plans have been changed so that people do not have to spend as much time at these facilities. Many medical appointments are being spread out to avoid close contact between people. More appointments are being made over the phone or online and hospital stays after surgery have been shortened. In some cases, fewer in-person visits are required to complete chemotherapy or radiation therapy.

The Report Includes

  • An overview of the global markets for oncology diagnostics

  • Estimation of the market size and analyses of market trends, with data from 2019 to 2020 and projection of CAGR through 2025

  • Market share analysis of oncology diagnostics by application, product, end-user and region, and evaluation of market size and forecast, and detailed analysis of drivers, challenges and opportunities affecting the market growth

  • Highlights of the current and future market potential of oncology diagnostics and a detailed analysis of the regulatory landscape, complications and prevalence of cancer

  • Details of major advances in technologies and products, ongoing activities and pipeline analysis of new products in the oncology diagnostics industry

  • Details about symptoms, progression and epidemiology of COVID-19 and discussion on the impact of COVID-19 pandemic on the medical industry as well as on oncology diagnostics market

  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies

  • Comprehensive company profiles of major players of the industry, including Abbott, Agilent, bioMerieux, General Electric Co., Roche, Siemens and Thermo Fisher Scientific

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Medical Device Regulations

  • Medical Device Definition and Classification

  • Regulations in the U.S.

  • Regulations in Europe

  • Regulations in Japan

Chapter 4 Oncology Diagnostics: Market Background

  • Cancer

  • Cancer Cells versus Normal Cells

  • Types of Cancer

  • Pipeline

Chapter 5 Oncology Diagnostics: Market Dynamics

  • Market Dynamics

  • Drivers

  • Market Restraints

Chapter 6 Impact of COVID-19 Pandemic

  • Introduction

  • Outbreak

  • Spread of Disease

  • Impact on MedTech

  • Elective and Noncritical Procedures

  • Shift in Manufacturing

  • Regulatory Delays, Clinical Trials and Product Launches

  • Supply Chain Disruptions

  • Medical Tourism

  • Impact of COVID-19 on the Global Economy

  • Government Expenditures on COVID-19

  • Impact on Insurance Providers

  • Impact of COVID-19 on Oncology

  • Impact on Early Cancer Diagnosis

  • Impact on Cancer Research

  • COVID-19 and Reimagining Cancer Care

  • Significant Declines in Testing and Diagnosis

  • Public Health Impact of COVID-19 Across the Cancer Continuum

Chapter 7 Market Breakdown by Product Category

  • Introduction

  • Diagnostic Imaging

  • Market Size and Forecast

  • Market Analysis

  • Endoscopy

  • Biopsies

  • Immunohistochemistry

  • In Situ Hybridization

  • Tumor Biomarker Tests

Chapter 8 Market Breakdown by Application

  • Breast Cancer

  • Lung Cancer

  • Colorectal Cancer

  • Prostate Cancer

  • Liver Cancer

Chapter 9 Market Breakdown by End User

  • Hospitals

  • Diagnostic Imaging Centers

  • Research Institutes

Chapter 10 Market Breakdown by Region

Chapter 11 Competitive Landscape

  • Mergers and Acquisitions

  • Strategic Alliances

Chapter 12 Company Profiles

  • Abbott

  • Agilent Technologies Inc.

  • Biomerieux Sa

  • Biocartis Nv

  • Diasorin S.P.A.

  • F. Hoffmann-La Roche Ag

  • General Electric Co.

  • Koninklijke Philips N.V.

  • Siemens Healthcare Gmbh

  • Thermo Fisher Scientific

For more information about this report visit https://www.researchandmarkets.com/r/cw4i4a

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting